Project title: low-dose erlotinib and mesalamine for prevention of colitis-associated colorectal cancer (CAC)
Active Awarded Last action
- Contract number
- 75N91025F00001
- Awardee
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,324,125
Award facts
- Opportunity
-
- TORFP2025E01 Solicitation number
- Contract value 100% obligated
- $1,324,125.00 Current and potential, with all options
- Completion date 43% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost Sharing
- Place of performance
- Houston, TX 77030, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $632,547 | |
| Original award | $691,578 |
About this award
The National Cancer Institute issued a delivery order to The University of Texas MD Anderson Cancer Center on September 25, 2025, for low-dose erlotinib and mesalamine for prevention of colitis-associated colorectal cancer, with a ceiling value of $1,324,125 under the PRECLINICAL EFFICACY & INTERMEDIATE ENDPOINT BIOMARKERS IDIQ.
The parent IDIQ supports preclinical drug development and biomarker discovery for cancer prevention research through the National Cancer Institute. Place of performance is Houston, TX. The order is structured as cost-sharing and runs through March 24, 2028.
Quick answers
Who was awarded contract 75N91025F00001?
75N91025F00001 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on September 25, 2025.
How much is contract 75N91025F00001 worth?
The government has obligated $1,324,125 on 75N91025F00001.
Is contract 75N91025F00001 an order under another contract?
Yes. 75N91025F00001 is a delivery order under 75N91024D00004, an indefinite delivery contract, on PRECLINICAL EFFICACY & INTERMEDIATE ENDPOINT BIOMARKERS IDIQ.
Was contract 75N91025F00001 competed?
The extent of competition for 75N91025F00001 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award